CC-930
Phase 2Small molecule
Bristol-Myers SquibbCC-930 is one of 52 small molecule programs targeting Discoid Lupus Erythematosus. It is currently in Phase 2.
2
Indications
2
Total Trials
0
Active Trials
51
Competitors
Pipeline
Status by Indication[3][1]
Indication
Competition
Competitive Landscape
179 competitors in Idiopathic Pulmonary Fibrosis
#DrugCompanyPhaseTrials
1Thalomid
Bristol-Myers SquibbPhase 3
Tracleer
Johnson & JohnsonPhase 3
Prevacid
TakedaPhase 3
Letairis
GileadPhase 3
Gleevec
NovartisPhase 3
MS Contin
Merck & Co.Phase 3
Coumadin
AAbbott
Phase 3
Cytoxan
BBaxter Healthcare Corporation
Phase 3
Jascayd
Boehringer IngelheimPhase 3
Bactrim
UUniversity of California, San Francisco
Phase 3
Ranked by pipeline maturity and clinical activity. Current drug highlighted in teal.
Clinical
Trials by Indication[1]
Sources
References
- [1]
- [2]
- [3]Open Targets Platform — Drug–disease associations for CC-930. EMBL-EBI & Wellcome Sanger Institute.
- [4]
Details
Drug Info
Quick Facts
- Modality
- Small molecule[2]
- Highest Phase
- Phase 2[1]
- Company